Effects of extensive splenomegaly in patients with myelofibrosis undergoing a reduced intensity allogeneic stem cell transplantation

被引：44

作者：

Ciurea, Stefan O. ^{[1
]}

Sadegi, Barry ^{[2
]}

Wilbur, Andrew ^{[2
]}

Alagiozian-Angelova, Victoria ^{[3
]}

Gaitonde, Sujata ^{[3
]}

Dobogai, Lisa C. ^{[1
]}

Akard, Luke P. ^{[4
]}

Hoffman, Ronald ^{[5
]}

Rondelli, Damiano ^{[1
]}

机构：

[1] Univ Illinois, Hematol Oncol Sect, Coll Med, Div Hematol,Dept Med, Chicago, IL 60612 USA

[2] Univ Illinois, Coll Med, Dept Radiol, Chicago, IL 60612 USA

[3] Univ Illinois, Coll Med, Div Hematopathol, Dept Pathol, Chicago, IL 60612 USA

[4] Indiana Blood & Marrow Transplantat Program, Indianapolis, IN USA

[5] Mt Sinai Sch Med, Hematol Oncol Sect, New York, NY USA

来源：

BRITISH JOURNAL OF HAEMATOLOGY | 2008年 / 141卷 / 01期

关键词：

myeloproliferative disorder; splenomegaly; reduced-intensity conditioning stem cell transplantation; myelofibrosis;

D O I：

10.1111/j.1365-2141.2008.07010.x

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Changes in spleen size postallogeneic haematopoietic stem cell transplantation (HSCT) in patients with primary myelofibrosis have been poorly characterized. We analysed 10 patients with myelofibrosis and splenomegaly following a reduced-intensity allogeneic HSCT. All patients fully engrafted donor cells including five patients with extensive splenomegaly. Extensive splenomegaly was associated with a prolonged time to neutrophil and platelet recovery. In all 10 patients, a progressive reduction of splenomegaly was documented within 12 months post-transplant and paralleled the reduction of marrow fibrosis. These findings suggest that myelofibrosis patients with extensive splenomegaly may proceed with allogeneic HSCT without prior splenectomy.

引用

页码：80 / 83

页数：4

共 12 条

[1] The Italian consensus conference on diagnostic criteria for myelofibrosis with myeloid metaplasia
Barosi, G
Ambrosetti, A
Finelli, C
Grossi, A
Leoni, P
Liberato, NL
Petti, MC
Pogliani, E
Ricetti, M
Rupoli, S
Visani, G
Tura, S
[J]. BRITISH JOURNAL OF HAEMATOLOGY, 1999, 104 (04) : 730 - 737
[2] Determination of splenomegaly by CT: Is there a place for a single measurement?
Bezerra, AS
D'Ippolito, G
Faintuch, S
Szejnfeld, J
Ahmed, M
[J]. AMERICAN JOURNAL OF ROENTGENOLOGY, 2005, 184 (05) : 1510 - 1513
[3] Byrne JL, 2000, BRIT J HAEMATOL, V108, P430
[4] Dupriez B, 1996, BLOOD, V88, P1013
[5] Philadelphia chromosome-negative myeloproliferative disorders: Biology and treatment
Hoffman, Ronald
Prchal, Josef T.
Samuelson, Scott
Ciurea, Stefan O.
Rondelli, Damiano
[J]. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2007, 13 (01) : 64 - 72
[6] Pilot study of reduced-intensity conditioning followed by allogeneic stem cell transplantation from related and unrelated donors in patients with myelofibrosis
Kröger, N
Zabelina, T
Schieder, H
Panse, J
Ayuk, F
Stute, N
Fehse, N
Waschke, O
Fehse, B
Kvasnicka, HM
Thiele, J
Zander, A
[J]. BRITISH JOURNAL OF HAEMATOLOGY, 2005, 128 (05) : 690 - 697
[7] Splenectomy and hemopoietic stem cell transplantation for myelofibrosis
Li, ZH
Gooley, T
Appelbaum, FR
Deeg, HJ
[J]. BLOOD, 2001, 97 (07) : 2180 - 2181
[8] Palliative goals, patient selection, and perioperative platelet management - Outcomes and lessons from 3 decades of splenectomy for myelofibrosis with myeloid metaplasia at the Mayo Clinic
Mesa, Ruben A.
Nagorney, David S.
Schwager, Susan
Allred, Jacob
Tefferi, Ayalew
[J]. CANCER, 2006, 107 (02) : 361 - 370
[9] Studies of the site and distribution of CD34+cells in idiopathic myelofibrosis
Ni, HY
Barosi, G
Rondelli, D
Hoffman, R
[J]. AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 2005, 123 (06) : 833 - 839
[10] Allogeneic hematopoietic stern-cell transplantation with reduced-intensity conditioning in intermediate- or high-risk patients with myelofibrosis with myeloid metaplasia
Rondelli, D
Barosi, G
Bacigalupo, A
Prchal, JT
Popat, U
Alessandrino, EP
Spivak, JL
Smith, BD
Klingemann, HG
Fruchtman, S
Hoffman, R
[J]. BLOOD, 2005, 105 (10) : 4115 - 4119

← 1 2 →